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1. INTRODUCTION 
        The ‘lupus’ term has its root in Latin language which means ‘wolf’ 
and was used for the first time to describe skin lesions which are erosive 
and it resembles a ‘wolf’s bite’. Ferdinand von Hebra, a physician from 
Viennese introduced the metaphor ‘butterfly’ to portray ‘malar rash’ in 
1846. He used the term ‘lupus erythematosus’ to illustrate in his book 
‘Atlas of Skin Diseases’ in 1856. Moriz Kaposi was the first one to 
recognize lupus as a systemic disease with visceral manifestations. After 
the discovery of ‘LE’ cell by Hargraves, Morton and Richmond in 1948 
at Mayo Clinic the modern age began in SLE. In late 1950’s it was 
discovered that lupus patients had high levels of circulating 
autoantibodies against nuclear structures (anti-nuclear autoantibodies; 
ANA) and diagnostic immunofluorescence assays were developed for the 
demonstration of ANAs.  
It is now recognized that systemic lupus erythematosus (SLE) is a 
chronic autoimmune disease with involvement of multiple systems. This 
disease presents with a variety of clinical manifestations and the course of 
the disease is highly variable with several exacerbations and remissions. 
During the course of the disease, a range of psychiatric manifestations 
have been reported. It is said that the prevalence of psychiatric morbidity, 
notably anxiety and mood disorders is common. The reported prevalence 
rates range from 17% to 75% (Shehata et al, 2011). Apart from 
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psychiatric manifestations, neurological disorders like stroke, seizure and 
headache have also been reported. The prevalence of neuropsychiatric 
manifestations has influenced the classificatory system in recognizing 
two types of SLE namely, neuropsychiatric SLE (NPSLE) and non-
NPSLE patients. Cognitive impairment is important parameter in NPSLE.  
Despite its importance and relevance, studies in India related to 
assessment of psychiatric manifestations are scanty and the present study 
is an attempt at assessment of psychiatric manifestations in patients with 
SLE.  
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2. REVIEW OF LITERATURE 
DEFINITION AND CLASSIFICATION 
        “Systemic lupus erythematosus (SLE) is a chronic relapsing 
remitting autoimmune disorder mediated by the immune-complex and 
characterized by its protean clinical manifestation and multisystem 
involvement”. The disease occurs commonly in young women and the 
severity varies from mild symptoms like a simple rash to more complex 
problems like arthritis and disease is characterized by involvement of 
renal and nervous system (Pisetsky 1997). The classification of SLE is by 
11 criteria suggested by the American College of Rheumatology (ACR) 
and later revised (Hochberg 1997, Tan et al 1982). 
 
AMERICAN RHEUMATISM ASSOCIATION (ARA) 1997 REVISED 
CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC LUPUS 
ERYTHEMATOSUS 
                                    
“1. Malar rash  Fixed erythema, flat or raised, over the malar 
eminences, tending to spare the nasolabial folds. 
2. Discoid rash  Erythematous raised patches with adherent keratotic       
scaling and follicular plugging; atrophic scarring may occur in older 
lesions. 
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3. Photosensitivity  Skin rash as a result of unusual reaction to 
sunlight, by patients’ history or physician observation.  
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually painless, 
observed by a Physician 
5. Arthritis  Nonerosive arthritis involving two or more peripheral 
joints, characterized by tenderness, swelling, or effusion 
6. Serositis  a) Pleuritis – convincing history of pleuritic pain or rub 
heard by a physician or evidence of pleural effusion 
                         OR 
            b) Pericarditis 
7. Renal disorder  a) Persistent proteinuria greater than 0.5 per day or    
greater than 3+ if quantification not performed 
                          OR 
                 b) Cellular casts 
8. Neurologic disorder  a) Seizures – in the absence of offending 
drugs or known metabolic derangements: e.g.,uremia, ketoacidosis, or 
electrolyte imbalance 
                           OR 
   b) Psychosis – in the absence of offending drugs or known metabolic 
derangements: e.g., uremia, ketoacidosis, or electrolyte imbalance 
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9. Hematologic disorder  a) Hemolytic anemia 
                               OR 
   b) Leukopenia – less than 4000/mm total on two or more occasions 
                                OR 
   c) Lymphopenia – less than 1500/mm on two or more occasions 
                                OR 
    d) Thrombocytopenia – less than 100000/mm in the absence of  
offending drugs 
10. Immunologic disorder  a) Anti-DNA: antibody to native DNA in 
abnormal titer  
                                OR 
             b) Anti-Sm: presence of antibody to Sm nuclear antigen 
                                          OR 
             c) Positive finding of antiphopsholipid antibodies 
11. Antinuclear antibody  An abnormal titer of antinuclear antibody 
at any time and in the absence of drugs known to be associated with drug-
induced lupus syndrome.” 
The classification is based on 11 criteria. SLE can be diagnosed 
when 4 or more of the 11 criteria are present, serially or simultaneously, 
during any interval of observation. 
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EPIDEMIOLOGY 
SLE is a worldwide disease; incidence peaks from 15 to 40 years of 
age with an average age of 32 years for disease onset in women while 40 
years of age for men (Pisetsky 1997). Multiple organs are affected in 
women 9 times more commonly than men (Muscal et al 2010). 90% of 
women are in child bearing age; people of both sex, all ages, and all 
ethnic groups are susceptible. Incidence and prevalence rates vary in the 
world depending on genetic and environmental factors. The incidence is 
2.4 % per 100,000 across genders and race, 9.2 % per 100,000 for black 
woman and 3.5 per 100,000 for white woman. It is more common in 
African-Americans, African-Caribbeans and Asians, than in Caucasians.  
 CLINICAL MANIFESTIONS 
General features of SLE include fatigue, malaise, fever and weight 
loss (Pisetsky 1997). Fatigue occurs in almost all patients. Low-grade 
fever is common; it may reflect active disease or infection. Weight loss 
occurs in about 60% of patients (Schur 1996). 
Arthritis and/or arthralgia affect 85 - 90% of patients during the 
course of illness. Arthritis predominantly affects the small joints of the 
wrists, hands and knees and can be deforming, although it does not 
produce joint erosion (Pisetsky 1997) 
The skin is involved in most SLE patients. A wide variety of skin 
manifestations include butterfly rash, discoid rash, photosensitivity, 
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livedo reticularis, mucous membrane lesions, alopecia and vasculitic skin 
lesions (Schur 1996).  
Pericarditis occurs in about 25% of patients (Rothfield 1996). 
Asymptomatic valvular lesions are detected by ECHO in 25% of patients 
but Libman-Sacks endocarditis is rarely seen. Occasionally it can be 
associated with antiphospholipid syndrome (APS) (Pettersson et al 2005). 
Lung is involved in about 50% of SLE patients with pleuritis being most 
common (Schur 1996)  
Renal disease is a frequent manifestation and develops in about 
50%-75% of patients (Schur 1996; Pisetsky 1997). Only few patients 
develop clinical renal disease, but most patients have some histologic 
abnormalities of the kidneys. The basic lesion is glomerulonephritis 
(GN). Renal biopsy is important in assessment of the nephritis pattern and 
the reversibility of the lesion.  
The 1982 World Health Organization grading system is currently used 
 TYPE1 : Normal kidney  
TYPE 2: Mesangial Glomerulonephritis  
TYPE 3: Focal segmental proliferative glomerulonephritis  
TYPE 4: Diffuse proliferative glomerulonephritis  
TYPE 5: Membranous glomerulonephritis  
TYPE 6: Chronic sclerosing glomerulonephritis 
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The higher the grade, more severe is the renal involvement (Burnett et al 
2005). 
 Muscle pain is a frequent complaint and accompanied occasionally 
by muscle wasting and weakness. True myositis is uncommon (Schur 
1996). 
One or more hematological abnormalities are present in nearly all 
patients with active disease (Rothfield 1996). They may reflect 
nonspecific inflammatory effects on bone marrow activity as well as 
binding of antibodies to elements of blood cell. Generalized 
lymphadenopathy is very common especially with active disease. Anti-
phospholipid antibodies (APL) can be found in 20-35% of patients with 
SLE (Pisetsky 1997).  
It may involve any ocular structure. The most common ocular 
manifestation is xerostomia (Rosenbaum et al 1996). 
Gastrointestinal symptoms are common, complaints include 
nausea, vomiting, dyspepsia and abdominal pain. Etiologies include 
bowel vasculitis, diffuse peritonitis, pancreatitis, inflammatory bowel 
disease or the use of medications (Schur 1996). 
Neuropsychiatric (NP) manifestations will be discussed later. 
The typical course is of flares and remissions, sometimes with 
many months or years between periods of clinical activity. The disease 
activity measures include monitoring laboratory tests and clinical 
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symptoms. The valid indices available to measure disease activity and 
damage index are: 
“SLAM - Systemic Lupus Activity Measure 
SLEDAI - Systemic Lupus Erythematosus Disease Activity Index  
LAI - Lupus Activity Index 
BILAG - British Isles Lupus Activity Group 
ECLAM - European Consensus Lupus Activity Measure.” 
The survival rate of SLE patients has increased when compared to 
the past forty years from 5 year survival of <50% by 1955 to survival rate 
of > 90% in recent studies. Leading cause of fatality in SLE patients is 
infection which may be owing to complication of either active disease or 
its treatment. Other major causes of death are pulmonary, renal or CNS 
failure and premature coronary artery disease (Boumpas et al 1995; Schur 
1996; Doria et al 2006). In a recent study SLE patients had a mortality 
rate four times higher when compared to common people and malignancy 
being the most common reason; it is followed by infection and vascular 
disease. Deaths in younger age were as a result of renal disease and late 
deaths were owing to atherosclerosis (Moss et al 2010). 
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PATHOGENESIS 
The etiology of SLE is not known. As with most autoimmune 
diseases, multiple factors likely effect it. 
Genetic susceptibility 
A strong familial aggregation is present in SLE and high frequency 
of first degree relatives being affected than others. In identical twins, the 
concordance rate is nearly 25-50% while in dizygotic twins is around 5%. 
These findings lead us to the fact that genetic factors are one of the 
important contributing factors for the causality of SLE. In most cases, 
multiple genes interact with one another to cause the disease but rarely 
single gene could lead on SLE. Linkage analyses have been used in 
increasing frequency now a day to find the susceptibility genes. An 
estimate says that for the disease to occur, at least four susceptibility 
genes should be inherited. Human leucocyte antigen (HLA) class II gene 
polymorphisms are implicated in susceptibility to SLE in general 
population. HLA DR2 and DR3 allele and SLE association is commonly 
present in patients belonging to various ethnicities and this association 
increases the risk of by fivefold for them to develop the disease. 
However, in general population, SLE cases are sporadic and with no 
genetic predisposing factors. This finding suggests that many 
environmental or yet unknown factors may also be contributing for the 
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causality of the disease (Mok & Lau 2001; Sawalha & Harley 2004; Tsao 
2004). 
Role of hormones 
Endogenous sex hormones have a role in predisposing the 
individual to the disease. SLE is a disease which is commonly seen in 
female gender and it usually flares up before puberty or after menopause. 
Oestrogen metabolism is disturbed in both male and female patients and 
plasma androgen levels are low in women who are having SLE. Usually, 
SLE flares up when the hormone levels are altered quickly. Further 
evidence suggests that activity as well as prognosis of SLE depends on 
the concentration of endogenous oestrogen. Prolactin, an 
immunostimulatory hormone, levels are raised in SLE. Hormones create 
an internal milieu which makes the person susceptible for the 
development of the disease (Mok & Lau 2001). 
Environmental triggers  
Genetic and the hormonal factors lead only to susceptibility for the 
development of the disease but the initiation is by environmental triggers 
and some factors which are exogenous. Environmental triggers suggested 
in the initiation of SLE are chemical and physical factors like drugs 
(procainamide, isoniazid, hydralazine, quinidine, methyl DOPA and 
chlorpromazine), hair dyes, tobacco smoke, aromatic amines, hydrazines 
and UV light. Some dietary factors like high intake of saturated fats have 
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been suspected to precipitate SLE. Theoretically, infectious agents such 
as viruses might flare up SLE by molecular mimicry. Viruses suspected 
to be involved in pathogenesis of SLE are Epstein-Barr virus, 
cytomegalovirus, parvovirus B19 and the retroviruses. Hormones and 
environmental oestrogens have been linked to autoimmune disorders. 
Hormonal replacement therapy and oral contraceptive pills are related to 
a mild risk of SLE initiation (Mongey et al 1996; Mok & Lau 2001, 
Manson & Isenberg 2003). 
Immunopathology            
Multiple immunologic pathologies are implicated for the initiation 
and clinical picture of SLE (Anolik & Sanz 2004). The basic pathological 
features are chronic inflammation and abnormalities in blood vessels 
(Mok & Lau 2001). The fundamental disturbance appears to be a 
dysfunction of immune system, with a loss of self-tolerance caused by 
alterations in B-cell functions. The disease is characterized by 
autoantibody production and immune-complex-mediated end-organ 
damage; both of them reflect the failure of immune tolerance (Burnett et 
al 2005; Tieng et al 2007). 
The central immunological disturbance is autoantibody production 
by B cells. There is evidence that depending on genetic background and 
specific environmental insults, the disease may be induced by a 
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breakdown of B-cell tolerance leading to the generation of pathogenic 
antibodies (Anolik & Sanz 2004). Autoantibodies for the nucleus, 
cytoplasm, and cell surface are usually found. In addition various 
autoantibodies may be used to diagnose, predict the disease 
manifestations and be helpful in monitoring the disease activity and 
response to treatment (Sawalha & Harley 2004). 
Antinuclear antibodies (ANA) are distinct and sensitive since it is 
present in more than 95% of the people suffering from SLE (Manson & 
Isenberg 2003; Mok & Lau 2001;Sawalha & Harley 2004). But ANA are 
not specific as it is present in other autoimmune, rheumatic, and 
infectious conditions and even in normal individuals. Diagnosis of SLE 
does not solely rest on the presence of ANA. Recent demonstration that 
patients with SLE may express ANA many decades or years before 
clinical disease sets in suggesting B-cell tolerance is an important factor 
in the pathogenesis of SLE and it is broken down early in the disease. 
This B-cell breakdown can lead to other immune malfunctions (Anolik & 
Sanz 2004; Sawalha & Harley 2004; Doria et al 2008). The antibodies 
with the highest specificity for the diagnosis of SLE are those directed 
toward dsDNA (Anti-dsDNA) (Mok & Lau 2001; Manson & Isenberg 
2003). Anti-dsDNA is not particularly sensitive because it may only be 
transiently detected in the course of disease. Other autoantibody which is 
unique in SLE is Anti-Sm antibodies (Sawalha et al 2004, Mok et al 
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2005). The other important antibody in SLE is anti-dsDNA antibodies 
and it is associated with glomerulonephritis. Raised anti-dsDNA antibody 
titers have been found in active lupus nephritis. Anti-dsDNA antibodies 
are deposited in various parts of the body but it has a selective deposition 
in the kidneys and this antibody deposition leads to inflammation. Anti-
dsDNA antibody titers vary with time but not so in the case of anti Sm 
antibody titres. In addition to the above said antibodies, a host of other 
autoantibodies are present in SLE. The antigens against which the 
antibodies are produced depends on patient ethnicity or particular disease 
manifestations (Manson & Isenberg 2003)  
T cell functions are also aberrant in SLE patients. The number of 
activated T cells has been found to be increased in peripheral blood in 
SLE patients. The activated T cells act upon the B cells and induce it to 
produce autoantibodies (Mok & Lau 2001; Hoffman 2004; Kyttaris et al 
2004). T-cells, which suppress the self-directed B-cells, also malfunction 
in SLE (Manson & Isenberg 2003). 
Cytokines are proteins, low in molecular weight and act as immune 
system modulators. T-helper cells secrete Interleukin-10 (IL-10) which 
stimulates the B-cell for its proliferation and antibody production. The 
serum concentrations of IL-10 are significantly higher in SLE patients. 
Research findings show us that IL-10 is responsible for the 
overproduction of antibodies observed in SLE (Mok & Lau 2001; 
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Manson & Isenberg 2003). Tumour necrosis factor α (TNFα) gives some 
protection from SLE (Manson & Isenberg 2003). 
During the flare ups of SLE, there is a diffuse vasculopathy in 
endothelium. Adhesion molecules also mediate some cellular interactions 
which lead on to inflammatory process. Up regulation of Vascular cell 
adhesion molecule-1 (VCAMI) is seen in SLE (Merrill et al 2005). 
COMMON ANTINUCLEAR ANTIBODIES IN SLE (Sawalha & Harley 2004). 
____________________________________________________________________ 
Autoantibody          Frequency (%)       Autoantigen 
_____________________________________________________________________ 
Anti-dsDNA            50-60               DNA double helix 
Anti-Sm                10-25               Spliceosomal snRNP 
Anti-Ro (SS-A)          25-40               60-kDa or 52-kDa proteins 
Anti-La (SS-B)           10-15               48-kDa proteins 
Anti-Ribosomal P        15                 Ribosomal phosphoproteins P0, P1, P2 
Anti-nRNP              23-40              Spliceosomal snRNP 
Anti-Histone             50-70              H1, H2A, H2B, H3, H4, H5 
Anti-Ku                 20-40              p70/80 proteins 
_____________________________________________________________________ 
dsDNA, double-stranded DNA; Sm, Smith; snRNP, small nuclear ribonucleoprotein; 
nRNP, nuclear ribonucleoprotein. 
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Apoptosis 
      Evidence implicates apoptosis, programmed cell death, is a way by 
which propagation of SLE may happen and it is precipitated by various 
factors. This results in elevation in antibody production. Recent literature 
shows that there is a defect in apoptotic cell clearance function in SLE. 
The reason could be the deficiency of early complement proteins, such as 
C2, C4, or C1q and patients with these deficiencies may develop into 
severe lupus-like disease early in life (Mok & Lau 2001; Manson & 
Isenberg 2003). There is a high concentration of microparticles, which are 
small membrane-bound vesicles that reduces phagocytosis of apoptotic 
cells. In SLE, there have been measured raised levels of microparticles 
(Antwi-Baffour et al 2010). 
Definition and classification of neuropsychiatric SLE (NPSLE) 
       “Neurologic and psychiatric manifestations have been termed CNS 
vasculitis, CNS lupus, neurolupus, neuropsychiatric lupus, or lupus 
cerebritis”. It includes neurologic syndromes of central, peripheral, and 
autonomic nervous system. It is estimated that two thirds of NP 
manifestations in SLE are not directly related to active NPSLE (primary 
NPSLE) but instead are a consequence of SLE like infections, drugs and 
hypertensive and metabolic complications (secondary NPSLE). The NP 
symptoms vary in their clinical expression from focal to diffuse 
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manifestations (Kovacs et al 1993). They can also be divided to major 
symptoms, including e.g. Cerebrovascular events, seizures and psychosis; 
and minor symptoms e.g. headaches, mood swings and cognitive 
complaints (Denburg et al 1993). As there is no one test available 
sensitive and specific enough to diagnose NPSLE, the diagnosis and 
management of each patient is based on clinical and other investigations 
and tests (Brey 2007). NPSLE syndromes can occur at any time of the 
disease course and even when there is no disease activity is present 
outside the nervous system. In approximately 28% - 40% of the patients 
predisposed to develop SLE, NPSLE symptoms occur before the start of 
SLE, or while diagnosis and in 63% of persons NPSLE symptoms can be 
seen after one year of diagnosis (Brey 2007; Burnett et al 2005). NPSLE 
has been reported to be a prognostic factor for a poor long-term outcome 
in SLE. In a recent study, the occurrence of NP events in newly 
diagnosed patients, a relationship was seen between reduction in quality 
of life scores and increased organ damage (Hanly et al 2007). The 
mortality rate in NPSLE has varied from 7% to 40% and NP involvement 
constitutes the second prevalent reason for death in SLE after renal 
failure (Kovacs et al 1993; Sibbitt et al 1999). 
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The Neuropsychiatric Syndromes In SLE According To The 
American College Of Rheumatology Nomenclature And Case 
Definitions (ACR Ad Hoc Committee On Neuropsychiatric Lupus 
Nomenclature 1999). 
Central Nervous System                        
Aseptic meningitis                                     
Cerebrovascular disease                        
Demyelinating syndrome                        
Headache                                     
Movement disorder (chorea)                     
Myelopathy                                  
Seizure disorders                              
Acute confusional state                         
Anxiety disorder 
Cognitive dysfunction 
Mood disorder 
Psychosis 
Peripheral nervous system 
Acute inflammatory demyelinating Polyradiculoneuropathy 
 
Autonomic disorder Mononeuropathy, single/multiplex 
Myasthenia gravis 
Neuropathy, cranial Plexopathy 
Polyneuropathy 
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Clinical features of NPSLE 
Central nervous system 
Aseptic meningitis 
       Aseptic meningitis is a non-infectious meningeal syndrome which 
may present with some nuchal rigidity and increased cells in 
cerebrospinal fluid. Aseptic meningitis is not a very presentation, but it 
can occur in early phase of disease. It has multiple factors for initiation. 
The immune complex deposition in the choroid plexus has been 
suspected in pathogenesis. When making a diagnosis of aseptic 
meningitis as a part of active SLE, nonsteroidal anti-inflammatory drugs 
(NSAID) as a potential cause must be excluded. Aseptic meningitis as a 
side effect of NSAID is probably more common in SLE patients than in 
others (Kovacs et al 1993; Ostensen & Villiger 2001; Jennekens & Kater 
2002). 
        According to the ACR case definitions, “A diagnosis of aseptic 
meningitis can be made when we observe symptoms and signs such as 
acute or subacute onset of headache, photophobia, neck stiffness and 
fever, signs of meningeal irritation and abnormal CSF (ACR 1999)”. 
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Cerebrovascular 
       Stroke occurs in patients with SLE by a variety of mechanisms, 
including cardiogenic embolus, large-vessel occlusion or stenosis, small-
vessel ischemia, and intracranial hemorrhage. In SLE, ischaemic stroke is 
correlated to the presence of circulating antiphospholipid antibodies and 
premature atherosclerosis (Jennekens & Kater 2002). The estimated 
frequency of strokes and transient ischemic attacks (TIA) among SLE 
patients ranges from 3% to 19 %. Futrell and Millikan reviewed 105 
patients with SLE and found that the majority of patients had their first 
cerebrovascular accident within the first 5 years of illness and the mean 
age of patients at the time of stroke was 40 years (Futrell & Millikan 
1989). SLE patients have a high risk for recurrent cerebral ischemia and 
the risk may be over 50% (Kovacs et al 1993). 
       The ACR case definitions suggest the following diagnostic criteria 
for cerebrovascular disease: “stroke syndrome, TIA, chronic multifocal 
disease, subarachnoid and intracranial hemorrhage and sinus thrombosis; 
supporting radioimaging study must be included and antiphospholipid 
antibodies (APL) recorded (ACR 1999)”. In newer studies using ACR 
case definitions the prevalence of cerebrovascular disease has varied from 
2% to 24% (Brey et al 2002; Sanna et al 2002; Afeltra et al 2003; Hanly 
et al 2004) 
 27 
Demyelinating syndrome 
       The phrase “lupoid sclerosis” represents patients with SLE having 
complex neurologic deficits. It refers to relapsing myelopathy or optic 
neuropathy (ACR 1999; Jennekens & Kater 2002; Hanly et al 2005). In 
CSF, oligoclonal bands may be seen and multifocal white matter bright 
spots may be seen on magnetic resonance imaging (MRI) studies.  
        ACR case definitions recommend the term “demyelinating 
syndrome” to be used instead of “lupoid sclerosis” (ACR 1999). 
Headache 
        Headache is a common symptom both in SLE patients and in the 
normal population; whether there is a unique syndrome attributable to 
SLE is debated (Liang & Karlson 1984; ACR 1999, Hanly et al 2005). 
Studies have reported the prevalence ranging from 30% to 65% 
(Mitsikostas et al 2004). Isenberg et al reported the first controlled trial 
that concludes migraine with aura was more common in SLE than control 
population (Isenberg et al 1982). The incidence of migraine was 
prospectively studied in 90 patients and controls; a history of migraine in 
SLE patient group (34%) was approximately twice as common as in 
controls. An association between migraine and SLE disease activity was 
found too (Markus & Hopkinson 1992). In two recent controlled studies 
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the prevalence of headache in SLE has been investigated. In the first one, 
migraine was notably more common among patients with SLE when 
compared with patients with rheumatoid arthritis (RA), and related with 
SLE activity and organ damage measured by SLICC (Appenzeller & 
Costallat 2004). In another study, headaches were also more widespread 
in SLE patients than in RA patients. The scores for SLE disease activity 
or damage, functional disability and quality of life were similar between 
patients who suffered from SLE headache compared to those without 
SLE headache (Weder-Cisneros et al 2004). Both studies agreed that 
Raynaud`s phenomenon is related either with migraine or headache in 
general in patients with SLE.  
       ACR case definitions includes “migraine without aura, migraine with 
aura, cluster headache, tension headache, headache from intracranial 
hypertension and intractable, nonspecific headache ( ACR 1999)”. 
Movement disorder (chorea) 
        Although a number of movement disorders have been reported in 
SLE, the ACR case definitions accepts only chorea and it is the most 
common of these disorders (ACR 1999). It is recognized in less than 2% 
of cases and appear early in the course of illness and resolve 
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regardless of treatment (Kovacs et al 1993). It may be unilateral or 
generalized and is often accompanied by other focal neurologic signs or 
by changes in mental status. APLs are present in many SLE patients with 
chorea. The features in imaging and histopathological studies indicate 
abnormalities in basal ganglia, but it is not yet clear whether chorea is a 
result of antibody-induced neuronal dysfunction or due to vascular insult  
(Jennekens & Kater 2002). 
Myelopathy 
        Spinal cord disease is rare but well-described complication in SLE. 
Transverse myelitis is seen in less than 1% of patients and is 
characterized by the development of paraplegia, associated with back 
pain and sensory loss. It is usually seen in late course of the illness and 
carries a poor prognosis. Vasculitis is a prominent feature of the spinal 
cord on post-mortem. There has been an association with APL suggesting 
that the symptom might result from a coagulopathy or antibodies cross-
react with spinal cord phospholipids. Atleast 25% of patients who have 
myelopathy tend to develop optic neuropathy, frequently bilateral 
(Devic`syndrome). Secondary causes of myelopathy in SLE include an 
epidural or paraspinal abscess, epidural or subdural hematoma, disc 
herniation, and intramedullary or extramedullary tumor (Kovacs et al 
1993; Liang et al 1994; Brey 2000; Jennekens & Kater 2002). 
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Seizure disorders 
        Seizures are part of the revised ACR classification criteria for SLE. 
Prevalence of 8% to 35% has been reported in SLE patients, although 
fatal status epilepticus is rare. Seizures are usually generalized but focal 
seizures have also been documented (McCune et al 1988; Kovacs et al 
1993; Brey et al 2002, Sanna et al 2002). They may antedate a diagnosis 
of SLE by years or be the first manifestation of the disease (Liang & 
Karlson 1996). APLs have been found with increased frequency in SLE 
patients with epilepsy. The aetiology of seizures may be an APL-
associated cerebral infarction (Brey 2000). In a study of 519 patients, 60 
(11.7%) patients suffering with epileptic seizures were identified and all 
seven patients who presented with recurrent seizures had 
antiphospholipid syndrome (Appenzeller et al 2004).  
Acute Confusional state 
      The term organic brain syndrome is commonly used to define 
disturbed mental functioning with delirium, emotional inadequacy, 
impaired memory or concentration, incoherent speech and increased or 
decreased psychomotor activity in the absence of any secondary causes 
(Kovacs et al 1993). The incidence of organic brain syndrome has varied 
between 2-35% (Estes & Christian 1971; Grigor et al 1978; How et al 
1985; van Dam 1991). The disturbances characteristically develop over 
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hours to days and tend to have fluctuating course (ACR 1999). Metabolic 
abnormalities such as hypoxia and electrolyte abnormalities should be 
evaluated and corrected, CNS infection and hypertensive encephalopathy 
should be excluded (Liang & Karlson 1996; Hanly et al 2005). 
The term ‘acute confusional state’ is corresponding to the term 
‘delirium’, and according to the ACR nomenclature it ought to be used as 
a replacement for the term ‘organic brain syndrome’. ACR criteria 
includes “disturbed level of consciousness or arousal and acute or 
subacute alteration in cognition and/or a change in mood, affect or 
behavior. If only deficits in cognition exists and not other features it must 
be diagnosed as ‘cognitive dysfunction’ (ACR 1999)”. 
Depression 
It is the most frequently observed psychiatric disorder in SLE with 
a prevalence rate of about 16-51 %. Mood disorders might be owing to 
SLE disease activity or as a result of stress due to chronic illness. 
Role of steroid in causation of depression cannot be declined. In a 
study by Gift et al he found significantly higher scores of self reported 
depression amongst patients suffering from chronic obstructive 
pulmonary disease on prednisone than patients who were not on steroid 
therapy. 
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In a review by Ganz et al, depressive symptoms were found to be 
twice as common as organic symptoms and seven times as common as 
schizophreniform symptoms. 13 systemic lupus erythematosus patients 
had pure depressive symptoms and 11 patients had depressive symptoms 
mixed with schizophreniform or psychophysical or both but no evidence 
of organic symptoms.  
Mood disorders are associated with poor quality of life, number of 
hospitalizations and adjustment to illness.  
Nery et al evaluated the hypothesis that SLE disease activity is 
correlated to the presence and severity of major depression. 71 patients 
were examined for the presence and severity of major depressive 
disorder, psychosocial stressors, functional disability, SLE disease 
activity and cumulative damage. Patients suffering from major depression 
had greater severity of disease activity compared to those without it. 
Depression was also accompanied by life events and severity was directly 
correlated with disease activity as well as functional disability.  
Anxiety  
      Anemia, elevated CRF, HPA dysregulation, disfiguring skin rash, 
scarring alopecia and autoimmune thyroid dysfunction forms the base for 
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association between SLE and anxiety. The close association of anxiety 
and depression wherein both coexist makes it more in point. 
A study was done by Lindal et al among patients with systemic 
lupus erythematosus in Iceland and he found the most common disorder 
to be phobia (56 %), followed by generalized anxiety disorder (12%). 
Social phobia, Agoraphobia with and without panic and alcohol abuse 
were commonly found in SLE patients compared to population sample. 
This study concluded that perhaps high incidence of phobia might be 
related to disfiguring skin rashes in turn leading to social withdrawal. 
Psychosis  
Psychosis has been known to be accompanying SLE and SLE is 
considered as a differential diagnosis for acute psychosis in second 
decade of life. Reported prevalence varies from 2- 7% . Besides being 
etiologically related to psychosis these patients also encounter the risk of 
corticosteroid induced psychosis.  
               A study was done by Appenzeller et al to evaluate for frequency 
and risk factors of acute psychosis in SLE patients and to identify clinical 
as well as laboratory variables useful to differentiate acute psychosis as a 
primary manifestation of central nervous system from corticosteroid 
induced psychosis. 537 consecutive SLE patients were studied and 
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followed. They identified acute psychosis in 89 patients, among them 59 
had psychosis primary to central nervous system involvement, 29 were 
owing to corticosteroids and 2 were not related either to SLE or any other 
medications. Amongst 59 patients psychosis which was secondary to SLE 
at illness onset was seen in 19 of them and it was found to be associated 
with disease activity. During follow up psychosis was observed in 40 
patients and it was associated with positive antiphospholipid antibodies. 
28 patients had who were on corticosteroid therapy had nearly 38 
episodes of psychosis, all of them had severe disease activity and all were 
on prednisone in doses varying from 0.75 to 1mg/kg/day. Psychosis 
remitted once prednisone dose was tapered.  
       A review was done by Lewis DA et al to find the association between 
corticosteroid therapy and psychosis. He reviewed 79 cases from 
literature, 14 unreported steroid induced psychiatric syndromes and 29 
studies of clinical efficacy of steroids in medical illness. Findings 
indicated that psychiatric manifestations occur in around 5% of patients 
with corticosteroid therapy and most of them had affective and/or 
psychotic symptoms. Female sex, systemic lupus erythematosus and high 
doses of steroid could be risk factors. 
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Cognitive Dysfunction 
        The prevalence of cognitive abnormalities in SLE patients varies 
widely from 21-66% and is most probably due to differences in selection 
of patients and case-definition. Various neuropsychological tests have 
been used to assess nervous system integrity and various studies have 
been done, the important consistent finding in these studies has been that 
cognitive impairment is significantly more frequent in SLE patients than 
in matched samples of healthy subjects or other patients with systemic 
disease. In addition to this throughout the studies, subclinical cognitive 
impairment was detected. Even in the absence of overt NP symptoms few 
SLE patients were found to have significant cognitive problems. No 
specific pattern of cognitive dysfunction has been found for SLE but as 
reported in most studies deficits are found in attention and concentration, 
mild verbal memory, decreased verbal fluency, decreased psychomotor 
speed and executive dysfunction (Denburg et al 1993; Hanly et al 1998). 
Studies which used ACR case definitions have detected cognitive 
dysfunction to be between 52%-78% and cognitive functions were tested 
by neuropsychological instruments. 
Cognitive impairment in SLE patients is assumed to reflect CNS 
dysfunction. Possible etiology of cognitive disorder have been thought to 
be an antibody-mediated effect on neuronal functioning or small-vessel 
 36 
vasculopathy. (Denburg et al 1993; Denburg et al 2003; Hanly 2004). 
Many studies have been done to analyze the association between 
cognitive dysfunction and other clinical features but no aforementioned 
association was found. Presence of other overt neuropsychiatric 
symptoms anytime during the course of illness or during 
neuropsychological assessment is linked with cognitive impairment. 
Psychiatric disorders comorbidity have been found to be around 40 % in 
SLE patients with cognitive dysfunction. Manifold controversies exist 
regarding the usage of corticosteroids beyond cognitive dysfunction but 
most studies did not report such association. According to ACR 
nomenclature, criteria for diagnosis of cognitive dysfunction includes 
documentation by neuropsychological testing ( documented impairment 
in one or more of the cognitive domains : simple attention, complex 
attention, memory, language, reasoning / problem solving, visuo-spatial 
processing, psychomotor speed and executive functions ) and a 
significant decline with a former level of functioning.  
Peripheral nervous system 
Peripheral nervous system (PNS) manifestations are not studied 
extensively in SLE. The reported frequencies of abnormalities varies 
between 2% and 27% but when patients were evaluated using clinical 
electromyography and nerve conduction velocity studies, in upto 47% of 
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SLE patients clinical and subclinical peripheral nerve abnormalities were 
detected (Estes & Christian 1971; Feinglass et al 1976, Gibson & Myers 
1976; Grigor et al 1978; Omdal et al 1988; Hermosillo-Romo et al 2002). 
Most common peripheral neuropathy in SLE is a mild and symmetric 
distal sensory or sensorimotor neuropathy. This deficit is progressive over 
time but might fluctuate and may even be reversible (Goransson et al 
2006). In most patients, biopsy and electrodiagnostic findings shows 
features of vasculitic neuropathy (Rosenbaum et al 1996). Peripheral 
neuropathy is associated with renal failure and cutaneous vasculitis and it 
is also considered as an important prognostic factor for mortality in SLE 
(Hermosillo-Romo et al 2002). 
Despite having normal results in clinical evaluation and nerve 
conduction studies some patients tend to have these neuropathic 
symptoms. Small nerve fibers like C fibers convey perceptions of warmth 
and burning pain and A alpha fibers convey cold and sharp pain, a pure 
small-diameter nerve fiber neuropathy may be responsible for this. The 
most favourable method for proving the diagnosis of small fiber 
neuropathy is not established; measurement of heat-pain thresholds or 
warmth-detection thresholds and quantitative estimation of epidermal 
nerve fibers have been used. (Omdal et al 2002; Goransson et al 2006) 
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Acute ascending paralysis (the Guillan-Barre syndrome) has been 
reported in less than 1%; chronic inflammatory demyelinating 
polyneuropathy has also been linked to SLE. 
Mononeuritis multiplex in SLE is rare and almost always 
accompanied by evidence of active disease in other organs, although 
sometimes it may be the presenting feature of the disease (Martinez-
Taboada et al 1996). 
Carpal tunnel syndrome may be the most common peripheral nerve 
complication of SLE. 
Cranial nerve syndromes have been reported in 3-16% of SLE 
patients (Estes & Christian 1971; Feinglass et al 1976; Gibson & Myers 
1976; Grigor et al 1978). Optic neuropathy occurs in about 1% of patients 
and in some cases found to be in association with myelopathy. No 
particular clinical pattern predominates; visual loss, pain and visual field 
defects may appear. Vasculitis or small vessel disease are suggested as an 
etiology for optic neuropathy in SLE. Other cranial nerve disorders seen 
in SLE include trigeminal neuralgia and facial neuropathy (Rosenbaum et 
al 1996, Jennekens & Kater 2002). 
Myasthenia gravis is an autoimmune disorder which is mediated by 
antibodies to acetylcholine receptors and it may co-occur with other 
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diseases of immunologic origin and has been diagnosed in patients with 
SLE but is rare (Rosenbaum et al 1996; ACR 1999). 
Quality of life in SLE 
Measuring quality of life is an important construct in evaluating 
disease morbidity and treatment outcome. There are many measures 
which are disease specific like Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI), Systemic Lupus International Collaborating 
Clinic (SLICC), Systemic Lupus Activity Measure (SLAM) and are 
based on assessing disease activity by physician. They are primarily used 
for research plan and do not signify the social impact of disease or useful 
in measuring functioning and well being of the patients.  
A study was done by Jolly M et al to analyse the health related 
quality of life (HRQOL) of patients with systemic lupus erythematosus in 
comparison with other chronic diseases. He used self administered 
medical outcomes study short form-36 (SF-36) questionnaire in 90 
patients with systemic lupus erythematosus and in patients with other 
chronic illnesses like hypertension, adult onset diabetes mellitus, 
congestive heart failure (CHF), myocardial infarction and depression and 
it was done in general US population. He found that SLE patients were 
younger compared to patients of other chronic diseases except for 
depression. SLE patients scored significantly less than age matched 
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norms in all 8 domains, their quality-of-life was found to be significantly 
worse than patients with other chronic illnesses. CHF patients were no 
worse than SLE in regard to physical function, emotional as well as 
physical roles and vitality and they were significantly better in bodily 
pain, social functioning, mental health, and general health compared to 
SLE patients. Patients who suffered from depression scored low in role 
emotional and mental health domains but scored better in other domains 
compared to SLE patients. Systemic lupus erythematosus patients had 
significantly lower general health compared to other groups. Health 
related quality of life (HRQOL) was found to be worse significantly and 
at an early age all domains were affected compared to other patients with 
chronic diseases.  
In a study done by Lim LC et al he found significant correlation 
between disease activity and psychiatric morbidity among patients with 
SLE in Singaporean population. Severity of arthritis, myalgia and 
dermatological lesions were important factors, disease related 
psychological stress contributed significantly to psychopathology.  
A study was done using world health organization quality-of-life-
BREF (WHOQOL-BREF) by Khanna S et al in 73 SLE patients and 
activity of disease was quantified using Mexican Systemic Lupus 
Erythematosus Disease Activity Index (MEX-SLEDAI). Higher disease 
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activity scores were seen in association with lower QOL scores in 
physical and psychological domains but no such correlation were found 
in social and environmental domains. Physical as well as psychological 
domains were impaired in active lupus whereas social and environmental 
domains did not correlate with disease activity. Age or duration of illness 
did not affect the quality of life in any of the domains.  
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3. AIM & OBJECTIVES 
AIM 
To study the psychiatric manifestations in patients with systemic lupus 
erythematosus.  
OBJECTIVES 
1. To assess psychiatric manifestations such as anxiety, depression, 
psychotic symptoms and cognitive functioning among patients with 
systemic lupus erythematosus.  
2. To understand the clinical correlates of the psychiatric 
manifestations among patients with systemic lupus erythematosus. 
3. To assess the quality of life among these patients. 
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NULL HYPOTHESIS 
1. There is no significant difference between the presence of 
psychiatric manifestations among patients with systemic lupus 
erythematosus and normal healthy controls. 
2. There is no impairment in the quality of life in both the groups. 
3. There is no relationship between clinical characteristics, psychiatric 
morbidity and quality of life in both the groups. 
4. There is no difference between the socio demographic data in both 
the groups.  
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4. METHOD AND MATERIALS 
STUDY DESIGN 
A case control design was used in this study. 
CASES 
Fifty consecutive patients with systemic lupus erythematosus 
attending the Rheumatology outpatient department at the Government 
General hospital, Chennai. 
INCLUSION CRITERIA 
(1) Male and female patients attending the outpatient Rheumatology 
department, Government General Hospital, Chennai with a 
definitive diagnosis of systemic lupus erythematosus as per ACR 
classification 1999. 
(2) Participants between 18-60 years of age 
(3) Willing to provide informed consent for the participation in the 
study 
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EXCLUSION CRITERIA 
(1) Patients with other co-morbid physical illnesses such as diabetes, 
hypertension, infection, etc. 
(2) Patients with overlap syndrome. 
(3) Patients with known psychiatric illness before the onset of SLE. 
(4) Patients with a family history of psychiatric illness. 
(5) Refusal to participate in the research. 
(6) Refusal to provide informed consent for participation 
All the patients were given a thorough physical, neurological and 
psychiatric examination.  
CONTROLS 
Fifty healthy individuals from the relatives of the patients with 
systemic lupus erythematosus from a similar socio-economic background 
were recruited as the control group. Controls were also evaluated with 
physical, neurological and psychiatric examination. At recruitment, these 
controls were matched with the patients with SLE for age, gender and 
economic background.  
Both patients and controls were given the following measures.  
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MATERIALS USED 
A) Semi structured proforma to elicit socio economic and other 
information such as past history, family history, personal history, 
premorbid personality details, and clinical history 
B) MINI PLUS – structured clinical interview to assess psychiatric 
morbidity based on DSM IV.  
C) Hamilton Anxiety Rating Scale (HAM-A) 
D) Hospital Anxiety and Depression Scale (HADS) 
E) Hamilton Depression Rating Scale (HAM-D) 
F) Brief Psychiatric Rating Scale (BPRS) 
G) The Mini-Mental State Examination (MMSE) 
H) The Clock Drawing Test (CDT) 
I) World Health Organization Quality of Life (WHO QOL) BRFF 
TYPE OF STUDY 
Comparative study utilizing a case control design                                       
PERIOD OF STUDY    
May 2012 to October 2012  
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PLACE OF STUDY         
Department of Rheumatology 
Rajiv Gandhi Government General Hospital 
Madras Medical College and Research Institute, Chennai 
 
ETHICAL COMMITTEE 
The study was approved by the Institutional Ethical Committee, 
Madras Medical College vide letter No. 04082012  
All subjects (both patients and control group) gave informed 
consent for participation in written form. For those who were illiterate, 
consent form was read to them and they were requested to put their 
thumb impression, if they consent for participation.  
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STATISTICAL ANALYSIS 
The data collected from patients and controls were entered into an 
excel sheet. The data was analyzed using the computer software package 
developed by WHO and CDC (Epi Info 7, 2012). Continuous variables 
such as age, duration of treatment, dosage, scores in various rating scales 
used in study were expressed as mean ± standard deviation (SD). The 
categorical variables such as gender, education, occupation, income, 
marital status, family type, residence were represented as frequencies. A 
descriptive analysis was carried out for certain variables in the patient 
group. 
An independent sample ‘t’ test and ‘chi’ square test were used 
respectively for the comparative analysis of continuous and categorical 
variables between the two groups. Pearson's product-moment coefficient 
was used to understand the linear relationship between two continuous set 
of variables. For this study, significance level was set at p < 0.05.  
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SCALES and MEASURES USED IN THE STUDY 
1. M.I.N.I PLUS NEUROPSYCHIATRIC INTERVIEW 
It is a short structured clinical interview which has 20 separate 
modules for each disorder and is used to diagnose axis I disorders 
according to DSM IV or ICD 10 developed by Sheehan et al. It has been 
validated and reliability has been studied in comparison to the “SCID-P 
(structured clinical Interview for DSM IV)” and the “CIDI (Composite 
international Diagnostic Interview)” which is a structured interview 
developed by the World Health Organization for lay interviewers for 
ICD-10. It has a high inter-rater reliability and validity. It is a clinician 
administered scale and can be completed within 15minutes. M.I.N.I. Plus 
is divided into modules identified by letters with each letter 
corresponding to a diagnostic category. There are screening questions 
corresponding to the main criteria at the beginning of each diagnostic 
module except for psychotic disorders. Diagnostic box at the end of each 
module is given to indicate whether diagnostic criteria are met or not. 
2. MINI MENTAL STATE EXAMINATION 
Mini–mental state examination (MMSE) or Folstein test is a 30-
point questionnaire introduced by Folstein et al in 1975 used to screen for 
cognitive impairment. It is commonly used to screen for dementia and 
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also to estimate the severity of cognitive impairment and to follow the 
course of cognitive changes in an individual over time and serves as an 
effective way to monitor an individual's response to treatment. It is 
effective as a screening tool for cognitive impairment with older, 
community dwelling, hospitalized and institutionalized adults. It is also 
used as a research tool for screening cognitive disorders in 
epidemiological studies and follow cognitive changes in clinical trials.  
It has 11-questions which measures five areas of cognitive function 
including orientation, registration, attention and calculation, recall and 
language. Maximum score is 30, a score of 23 or lower is indicative of 
cognitive impairment. It takes around 10 minutes to administer and is 
easy to use repeatedly and routinely. 
It relies primarily on verbal response and reading and writing and 
as a result certain groups of people perform poorly even when their 
cognition is intact. They include patients who are hearing and visually 
impaired, intubated, have low English literacy or those with other 
communication disorders. 
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3. WORLD HEALTH ORGANISATION QUALITY OF LIFE 
SCALE-BREF SCALE (WHOQOL-BREF)  
“It is a 26-item version of the WHOQOL-100 based on a four 
domain structure which includes physical, psychological, social and 
environmental well being”. The facets are defined as those aspects of life 
that have contributed to a person’s quality of life. Among 26 items, 24 
make up the 4 domains of physical health (7 items), psychological health 
(6 items), social relationships (3 items) and environmental (8 items) and 
the rest 2 items measure overall QOL and general health. It uses a Likert 
type five point scale to assess the patient’s response, 24 of 26 questions 
are used to calculate. Raw scores on each domain are converted to 
transformed scores using an algorithm, first transformation converts 
scores to range from 4-20 and second transforms to 0-100 scale 
comparable with WHOQOL-100. All four domains demonstrate good 
internal consistency and test-retest reliability. The physical and 
psychological domains in particular demonstrate good construct validity.  
4. HOSPITAL ANXIETY AND DEPRESSION SCALE 
This is a self report scale developed by Zigmond and Snaith (1983) 
for use in hospital populations. It is a reliable tool for detecting symptoms 
of depression and anxiety in medically ill patients. It focuses mainly on 
subjective disturbance of mood rather than physical symptoms and 
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distinguishes psychiatric presentations from physical illness. Depressive 
subscale includes mostly symptoms of anhedonia and autonomic anxiety. 
Anxiety and depressive subscales are a valid measure of the severity of 
the emotional disorder.  
It contains of 7 items in each of the two scales and measures 
anxiety and depression which the patients experienced over the last one 
week. Each item in the scale has 4 scores from 0 to 3. Scores range from 
0-21 and graded as “0-7 = normal, 8-10 =mild, 11-14 =moderate, 15-21= 
severe”. Because of its ease, speed and acceptability it has been widely 
used in a variety of clinical populations where depression and anxiety 
might co-exist with physical illness.  
5. HAMILTON RATING SCALE FOR DEPRESSION (HAM-D) 
Popularly known as HAM-D, the scale consists of several item 
questionnaire used to assess depression and as a tool to evaluate recovery 
from depression. It was devised by Max Hamilton in 1960. The rating 
scale is intended for adults and used to grade the severity of depression. It 
was reported to be the gold standard in assessing depression on clinical 
grounds. Subsequently it was criticized by many researchers since it 
emphasises more on insomnia than the suicidal ideas or gestures. The 
original version consisted of 17 items (HSRD-17) the recent version 
consists of 21 questions. 
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Scoring patterns: 
“0-7 = Normal 
8-13 = Mild Depression 
14-18 = Moderate Depression 
19-22 = Severe Depression 
≥ 23 = Very Severe Depression” 
6. HAMILTON RATING SCALE FOR ANXIETY (HAM-A) 
Abbreviated as HAM-A, the rating scale consists of several item 
questionnaire used to assess anxiety and as a tool to evaluate recovery 
from anxiety. It was devised by Max Hamilton in 1959. It was one of the 
first rating scales to be published and it remains the widely used and well-
validated tool by psychiatrists. It should be administered by an 
experienced clinician. The time taken to administer is 10 to 20 mins, 
clinician must choose the possible replies to each question by questioning 
the patient and by detecting the patient's symptoms. The HAM-A probes 
14 parameters, each item is scored on a 5-point scale, ranging from 0=not 
present to 4=severe. The Sensitivity is 85.7% and the Specificity is 
63.5%. 
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Scoring patterns 
0-13normal 
14-17 mild anxiety 
18-24moderate  
>25severe 
 7. BRIEF PSYCHIATRIC RATING SCALE (BPRS) 
Is considered to be one of the oldest rating scales to measure 
psychosis and it was first published in 1962. The Brief Psychiatric Rating 
Scale (BPRS) is an inclusive 24-item symptom scale. The BPRS is used 
as part of a clinical interview in which the clinician makes observations 
amongst several symptomatic criteria and depends upon patient self-
report for other criteria. 
Items 1 through 14 are rated based on patients self-report during 
the clinical interview. Symptoms not assessed are marked as “NA.” Items 
7, 12 and 13 are also rated on observed behavior during the interview. 
Items 15 through 24 are rated based on the patient’s observed behavior or 
speech during the interview. 
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5. RESULTS AND DISCUSSION 
5.1 Descriptive analysis of the patient group 
5.1.1 Socio-demographic characteristics of the patients with systemic 
lupus erythematosus  
 
Table 1: Socio-demographic characteristics of the patients with 
systemic lupus erythematosus (n=50) 
 
 Socio 
demographic 
characters 
No of patients Percentage 
GENDER Male 
Female 
2 
48 
4 % 
96 % 
MARITAL 
STATUS 
Married 
Unmarried 
Others 
28 
15 
7 
56 % 
30 % 
14 % 
EDUCATION Illiterate  
Primary  
Middle  
High  
Intermediate  
Graduation/post-
graduation 
4 
5 
8 
23 
3 
7 
8 % 
10 % 
16 % 
46 % 
6 % 
14 % 
OCCUPATION Unemployed  
Unskilled  
Semiskilled  
Semi-profession 
Profession 
40 
2 
2 
5 
1 
80 % 
4 % 
4 % 
10 % 
2 % 
INCOME  <1000 
1000-2999 
3000-4999 
5000-7499 
7500-9999 
1 
11 
21 
16 
1 
2 % 
22 % 
42 % 
32 % 
2 % 
RESIDENCE  Urban  
Rural  
43 
7 
86 % 
14 % 
FAMILY TYPE  Joint  
Nuclear  
11 
39 
22 % 
78 % 
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The above table shows that the sample comprises of predominantly 
females 96 % and 4 % are males. Among them majority are married 56 
%, 30 % are not married, and 14 % are either separated, divorced or 
widow. Most of them have reached high school level of education (46 %), 
few are graduated (14%). Most of the subjects (80%) are housewives. 
Most of them have a monthly income of less than 5000 (42%). Majority 
of the patients with SLE belong to urban background (86%) and most of 
them live in nuclear families (78%). 
5.1.2 Clinical characteristics of the patients with systemic lupus 
erythematosus  
Table 2: Description of clinical data in patients with systemic lupus 
erythematosus 
 
Clinical 
variables 
No of 
patients Mean 
Standard 
deviation Median 
Duration of 
illness 
50 1.94 0.7 2 
Current dose of 
corticosteroids 
50 11.5 12 6.25 
Highest dose of 
corticosteroids 
50 27.9 18.2 20 
  
The above table shows that the mean duration of illness is 1.94 
years; and SLE patients received a mean dose of 11.5 mg corticosteroids 
with a mean highest dose of 27.9 mg corticosteroids. Most patients were 
treated with immunosuppressant drugs like cyclophosphamide, 
azathioprine along with corticosteroids prednisone.  
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5.1.3 Psychiatric manifestations as elicited by MINI plus 
neuropsychiatric interview  
 
Both patients and control group were given MINI PLUS 
neuropsychiatric interview to assess psychiatric morbidity based on DSM 
IV. None of the people in control group qualified for DSM IV diagnosis. 
Among patient group 16 (32%) qualified for a diagnosis of anxiety and 
26 (52%) qualified for a diagnosis of depression. Their symptoms were 
quantified using various rating scales as illustrated below.  
5.1.4 Psychiatric manifestations - anxiety and depression among 
patients with systemic lupus erythematosus 
 
 
Figure 1: Hospital anxiety and depression  
scale-anxiety score (HADS-A) 
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Table 3: Frequency Distribution of individual scores in HADS-A 
HADS-A 0 score in %  1 score in % 2 score in % 3 score in % 
Tension  22 54 20 4 
Frightful  50 18 26 6 
Worrying  20 36 38 8 
Relaxation  20 38 38 4 
Butterflies 
in stomach 
56 24 14 6 
Restless  36 44 20 4 
Panic  36 38 20 8 
 
As evaluated by Hospital Anxiety And Depression Scale-anxiety 
subscale (HADS-A) and depicted in figure 1 and table 3 patients scored 
high on questions which reported being tensed and frightened as if 
something awful is about to happen, having worrying thoughts most of 
the time, feeling restless and unable to sit at ease and feel relaxed. 
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Figure 2: Hospital anxiety and  
depression-depression scores (HADS-D) 
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Table 4: Frequency Distribution of  
individual scores in HADS-D 
HADS-D 0 score in  
% 
1 score in 
% 
2 score in 
% 
3 score in 
% 
Enjoyment  22 36 34 6 
Laughing  32 36 26 6 
Cheerful  38 36 20 6 
Slowed down  0 24 42 34 
Lost interest in 
appearance 
30 38 16 16 
Enthusiasm  36 42 12 8 
Entertainment  40 22 32 6 
 
As assessed by Hospital Anxiety And Depression Scale-Depression 
subscale (HADS-D) and depicted in figure 2 and table 4 patients scored 
high on questions which reported that they can’t enjoy the things which 
they once enjoyed and don’t feel cheerful most of the time, they feel as if 
they are slowed down very often and have no interest in their appearance 
and don’t take as much as care they should.  
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Figure 3: Hamilton anxiety scale (HAM-A) 
 
 
 
As depicted in figure 3 and rated by Hamilton Anxiety Scale 
(HAM-A) most of them had mild anxiety and one person had severe 
anxiety. They scored high on questions like having anxious mood, feeling 
tensed, suffering from somatic complaints like muscle aches or pains, 
cardiovascular symptoms like tachycardia, palpitations and autonomic 
symptoms like sweating, dry mouth.  
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Figure 4: Hamilton depression rating scale (HAM-D) 
 
 
As depicted in figure 4 and rated by Hamilton depression rating 
scale (HAM-D) a proportion of patients (N = 11) had mild depression and 
more (N =15) had moderate to severe level of depression. They scored 
high on questions like having depressed mood, ruminating over past 
errors or sinful deeds and feeling present illness is punishment, having 
suicidal ideas, suffering from insomnia, difficulty in carrying out 
activities, loss of concentration, worrying about minor matters and 
somatic symptoms.  
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Table 5: Frequency distribution of symptoms by rating  
scales (HAM-A & HAM-D) 
 
Rating 
Scales 
Absent Mild Moderate Severe Total 
HAM-A 34 13 2 1 50 
HAM-D 24 11 8 7 50 
 
The above table shows that 13 patients had mild anxiety (26 %),  
2 suffered from moderate level of anxiety (4%) and 1 had severe anxiety 
(2%) as rated by Hamilton anxiety scale (HAM-A). As rated by Hamilton 
depression rating scale (HAM-D) 11 have mild depression (22%), 8 had 
moderate depression (16%) and 7 patients suffered from severe 
depression (14%).  
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Table 6: Frequency distribution of  
symptoms by rating scale (HADS) 
 
 
Normal 
Borderline 
Abnormal 
Abnormal Total 
HADS-A 34 9 7 50 
HADS-D 26 14 10 50 
 
The above table shows that 16 patients (32%) had abnormal scores 
on anxiety scale in Hospital Anxiety and Depression Scale (HADS-A) 
and 24 patients (48%) had abnormal scores on depression scale  
(HADS-D).  
 
  
 65 
Table 7: Systemic lupus erythematosus patients subdivided on the 
basis of HAM-A and HAM-D SCORES 
 
 HAM-A 
HAM-D Absent Mild 
Significant 
(Moderate + Severe) 
Absent 19 5 0 
Mild 8 3 0 
Significant 
(Moderate + Severe ) 
7 5 3 
 
The above table shows that among these 50 patients, mixed anxiety 
and depression as elicited by Hamilton rating scales is not uncommon. 
Just more than a fifth of the patients with SLE (22%) have mixed anxiety 
and depression symptoms to a mild or significant level. Six percent of the 
patients have significant mixed anxiety and depression.  
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5.1.5 Psychiatric manifestations – psychotic symptoms among 
patients with systemic lupus erythematosus 
Figure 5: Brief Psychiatric Rating Scale 
 
 
 
As depicted in figure 5 and rated by brief psychiatric rating scale 
(BPRS) no frank psychotic symptoms were elicited and patients scored in 
questions such as somatic concern and preoccupation with physical 
health, anxiety, guilt feelings, tension, depressive mood.  
 
  
 67 
5.1.6 Psychiatric manifestations – cognitive functioning among 
patients with systemic lupus erythematosus 
 
Figure 6: Mini Mental Status Examination 
 
 
As rated by Mini Mental State Examination (MMSE) and depicted 
in figure 6 none of them scored below the cut off score of 23. It was 
observed that many patients had difficulty in copying the pentagon  
and impairment in recalling given objects, recalled either 1 or 2 objects 
out of 3.  
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Figure 7: Clock Drawing Test Scores 
 
 
As depicted in figure 7 and assessed by clock drawing test (CDT) 
and rated by scoring given by Shulman et al 1993 a score of 3 or more 
represented a cognitive deficit and in this sample, 18 % patients had 
cognitive impairment.  
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5.2 Relationship between clinical data and psychiatric manifestations 
 
5.2.1 Relationship between clinical data and anxiety and depression 
Table 8: Correlation coefficients of Clinical data with anxiety, 
depression and cognition 
Clinical data Rating scales Correlation 
coefficient  
‘p’ value  
 
 
Duration of illness 
 
HADS A 0.0 0.7972    NS 
HADS D 0.01 0.5924    NS 
HAM A 0.01 0.5499    NS 
HAM D 0.0 0.8866    NS 
CDT 0.03 0. 2160   NS 
MMSE 0.02 0.3641    NS 
 
Current dose of 
corticosteroids 
 
HADS A 0.0 0.6461    NS 
HADS D 0.04 0.1662    NS 
HAM A 0.0 0.7874    NS 
HAM D 0.05 0.1316    NS 
 
The above table demonstrates that clinical data such as duration of 
illness (SLE) and current dose of corticosteroids received by the 
individual does not have any significant association with the anxiety, 
depression and cognitive functioning elicited by various measures such as 
HADS, HAM-A, HAM-D, CDT and MMSE. Thus these psychiatric 
manifestations such as anxiety and depression are not related to clinical 
variables such as duration of disease and dose of corticosteroids.  
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5.2.2 Relationship between anxiety, depression and cognitive 
functioning 
Table 9: Correlation coefficients of anxiety, depression and cognition 
 
Anxiety / 
Depression 
rating scales 
Cognitive 
functioning 
rating scales 
Correlation 
coefficient ‘p’ value 
HADS D CDT 0.05 0.1180    NS 
HAM D CDT 0.04 0.1769    NS 
HADS A CDT 0.00 0.6849    NS 
HAM A CDT 0.01 0.5242    NS 
 
 
It was revealed that in nine patients the CDT scores were above 3, 
the cut-off for cognitive impairment. To understand whether the cognitive 
impairment was associated with the levels of anxiety or depression, 
correlation between these two sets of variables were carried out. Findings 
from the above table revealed that the there is no significant association 
between anxiety, depression as elicited by HADS, HAM-A, HAM-D and 
CDT scores. Thus the cognitive impairment seen in these patients is 
independent of anxiety and depression.  
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5.3 Comparison of patients with SLE and normal controls for 
demographic and clinical variables 
5.3.1 Comparison of cases and controls for demographic variables 
Table 10 Comparison of Patients with SLE  
with normal controls for Gender 
 
Gender Patients 
With SLE 
Control Df ‘chi’ square 
value 
‘p’value 
Males 2 2 1 0.2604 0.6098 
NS Females 48 48 
 
Table 11: Comparison of Patients with  
SLE with normal controls for Age 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 30.7 9.2 0.1658 0.8687 
NS 
Control 50 31 8.9 
 
Table 12: Comparison of Patients with SLE  
with normal controls for Family Type 
 
Family 
Type 
Cases Controls df ‘chi square 
value’ 
‘p’ 
value 
Joint 11 16      1 1.27 0.26 
NS Nuclear 39 34 
 
Table 13: Comparison Of Patients With  
SLE With Normal Controls For Income 
 
INCOME CASES CONTROLS df ‘chi square value’ ‘p’ value 
<5000 33 24      1 3.3 0.0690 
NS >5000 17 26 
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Table 14: Comparison of Patients With  
SLE With Normal Controls For Residence 
 
RESIDENCE CASES CONTROLS df 
‘chi 
square 
value’ 
‘p’ 
value 
URBAN 43 45 1 0.38 0.5382 
NS RURAL 07 6 
 
Table 15: Comparison Of Patients With  
SLE With Normal Controls For Marital status 
 
MARITAL 
STATUS 
CASES CONTROLS df ‘chi 
square 
value’ 
‘p’ value 
MARRIED 28 33 1 1.05 0.3053 
NS OTHERS  22 17 
 
Table 16: Comparison Of Patients With  
SLE With Normal Controls For Occupation 
 
OCCUPATION CASES CONTROLS df 
‘chi 
square 
value’ 
‘p’ 
value 
EMPLOYED 10 18 1 3.17 0.0747 
UNEMPLOYED 40 32 
 
All subjects in patient group and control group were compared for 
demographic characteristics such as age, gender, education, occupation, 
income, marital status, family type and residence. Data analysis 
demonstrates that there is no statistically significant difference between 
the two groups for the above variables. This shows that cases and controls 
are matched for various demographic characteristics.  
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5.3.2 Comparison of patients with SLE and control group for anxiety 
and depression 
Table 17:  
Comparison of Patients with SLE with normal  
controls for HAM-A scores 
 
Sample NUMBER MEAN SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 8.8 6.1 3.8 0.0002 
Control 50 4.9 3.5 
 
The above table compares total scores as obtained through 
Hamilton Anxiety Scale (HAM-A). The mean ± SD (8.8 ± 6.1) score of 
patients with SLE is greater than the mean ± SD (4.9 ±3.5) of the control 
group. This difference is significant statistically (p 0.0002). This shows 
that patients with SLE have more anxiety scores as revealed by HAM-A 
compared to healthy controls.  
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Table 18: Comparison of patients with  
SLE with normal controls for HADS-A scores 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 5.9 4 4.3 0.01 
Control 50 3.2 2 
 
The above table shows that the anxiety scores obtained through 
Hospital Anxiety and Depression Scale are higher among the patients 
with SLE compared with normal controls and such a difference between 
the mean scores is statistically significant (p 0.01).  
Increased anxiety disorder among SLE is reported commonly among 
SLE patients (Bachen et al 2009; Ghaydaa et al 2011; Hawro et al 2011). 
Elevated anxiety levels among patients with SLE could be attributed to 
the following factors: 
1. SLE is a chronic disease 
2. SLE produces skin manifestations inducing anxiety as skin 
manifestations can cause embarrassment in public 
3. The active disease process itself produces neuropsychiatric 
manifestations including anxiety symptoms 
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Table 19: Comparison of patients with  
SLE with normal controls for HAM-D scores 
 
Sample NUMBER MEAN SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 9.7 7.2 
4.1 0.0001 
Control 50 5.1 3.1 
 
The above table compares the total scores as obtained through 
Hamilton Depression Rating Scale (HAM-D). The mean ± SD (9.7 ± 
7.2) score of patients with SLE is greater than the mean ±SD (5.1 ±3.1) 
of the control group. This difference is significant statistically (p 0.0001). 
This shows that patients with SLE have more depressive scores as 
revealed by HAM-D compared to healthy controls.  
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Table 20: Comparison of patients with  
SLE with normal controls for HADS-D scores 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 7.2 4.9 4.3 0.01 
Control 50 4.1 2.2 
 
Comparison of mean scores obtained in HADS- D between the 
patients with SLE and normal control demonstrates that the scores are 
higher among patients with SLE and such a difference is statistically 
significant (p 0.01).  
High rates of depression have been reported in many studies in the 
literature (Purandare et al 1999; Mariana et al 2010). Depression among 
patients with SLE may be attributable to the following: 
1. As a part of the disease 
2. Can be caused by various medications (e.g., corticosteroids) used 
in treating the disease 
3. May be a reactive psychological disturbance owing to stress of 
having a chronic disease. 
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Table 21: Comparison of patients with  
SLE with normal controls for BPRS scores 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 22.1 4.3 
4.5 0.01 
Control 50 19.2 1.5 
 
The above table demonstrates that there is statistically significant 
difference (p 0.01) between patient and control group for psychotic 
symptoms as elicited by Brief Psychiatric Rating Scale ( BPRS ). In our 
sample psychotic symptoms among patients with SLE are infrequent but 
the elevation in the BPRS scores is primarily due to scores on symptoms 
such as somatic concern and preoccupation with physical health, anxiety, 
guilt feelings, tension, depressive mood. The lower frequency of 
psychotic symptoms is also reported in earlier studies (Purandare et al 
1999; Raghavendra et al 2012).  Pego-Reigosa and Isenberg in 2008 have 
reported in their study that psychosis is a rare manifestation of SLE; and 
it might be an initial manifestation of the disease, usually occurring in the 
first year of disease in few cases. Psychosis may be associated biological 
markers of lupus activity like ANA, anti-dsDNA.  
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Table 22: Comparison of Patients with  
SLE with normal controls for MMSE scores 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 29.4 1 2.3 0.02 
Control 50 29.7 0.4 
 
The above table shows a statistically significant difference for the 
total MMSE scores between the patient group and control group (p 0.02). 
Even though the descriptive analysis has identified that none has scored 
below the cut-off point of 23, yet compared with healthy controls there is 
a decline in cognitive functioning among patients with SLE.  
 
Table 23: Comparison of patients with  
SLE with normal controls for CDT scores 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 1.96 0.9 5.9 0.001 
Control 50 1.12 0.3 
 
Above table shows that the patient group have higher clock 
drawing test (CDT) scores compared with the control group. (patient’s 
mean 1.96, median 2 : controls mean 1.12,median 1.12 ). The difference 
between the 2 groups is statistically significant (p<0.001). Compared with 
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healthy controls patients with SLE appeared to have more cognitive 
disturbances. Nine of the patients (18%) have scored 3 or more in CDT. 
Such a decline in cognitive functioning could be due to either disease 
activity or attributable to psychiatric symptoms such as depression (Melo 
et al 2012). Hence the CDT scores, depression and anxiety scores in 
HAM-A and HAM-D were analysed using Pearson correlation coefficient 
(see table 9). Results show no statistically significant correlation between 
cognition, anxiety and depression. This concludes that they all are 
independent variables. 
Cognitive functioning decline is often reported among the patients 
with SLE (Maneeton et al, 2010). Cognitive abnormalities associated 
with SLE are impairment in immediate, delayed and retrieval of memory, 
impairment in visuospatial activities, poor attention and concentration, 
difficulties with abstract thinking and reduction in psychomotor speed 
(Anselm Mak et al 2009).  
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5.3.3 Comparison of patients with SLE with normal controls for 
quality of life  
 
5.3.3.1 Comparison of patients with SLE with normal controls for 
physical health  
 
Table 24 : Comparison of patients with  
SLE with normal controls for WHOQOL-  
DOMAIN 1 scores (0-100) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 49.9 7.45 1.76 0.08 
NS 
Control 50 52.7 8.57 
 
Table 25 : Comparison of patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 1 scores (4-20) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 11.98 1.22 1.76 0.08 
NS 
Control 50        12.44 1.38 
 
 This table illustrates that there is no statistically significant 
difference between the transformed scores on Domain 1 of WHOQOL-
BREF scale. This shows that the quality-of-life relating to physical health 
is not affected in patients with systemic lupus erythematosus and is 
comparable to normal controls.  
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5.3.3.2 Comparison of patients with SLE with normal controls for 
psychological health 
Table 26 : Comparison of patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 2 scores (0-100) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients With 
SLE 
50 47.7 10.2 3.04 0.003 
Control 50 53.68 9.2 
 
Table 27 : Comparison of patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 2 scores (4-20) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients With 
SLE 
50 11.62 1.63 3.06 0.0028 
Control 50            
12.58  
1.48 
 
The above table shows statistically significant difference between 
patient and control group for transformed scores on domain 2 of 
WHOQOL-BREF scale. This signifies that the psychological domain 
related quality-of-life is significantly impaired in SLE patients compared 
with normal controls. Such a finding is consistent with results obtained 
from other studies (Doria et al 2004; Rinaldi et al 2004).  
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5.3.3.3 Comparison of patients with SLE with normal controls for 
social relationships 
Table 28: Comparison of Patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 3 scores (0-100) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 53.58 17.43 0.53 0.59 
NS 
Control 50           55.3 14.6 
 
Table 29: Comparison of Patients with  
SLE with normal controls for 
WHOQOL-DOMAIN 3 scores (4-20) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50 12.58 2.78 0.54 0.58    
NS 
Control 50        12.86 2.33 
 
 This table shows no statistically significant difference between the 
transformed scores on Domain 3 of WHOQOL-BREF scale. This shows 
that the quality-of-life relating to social relationships are not affected in 
patients with systemic lupus erythematosus and is in comparison with 
normal controls.  
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5.3.3.4 Comparison of Patients with SLE with normal controls for 
environment 
Table 30: Comparison of Patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 4 scores (0-100) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50           
57.18 
11.36 0.34 0.73 
NS 
Control 50 57.92 10 
 
Table 31: Comparison of Patients with  
SLE with normal controls for WHOQOL- 
DOMAIN 4 scores (4-20) 
 
Sample Number Mean SD ‘t’ value ‘p’ value 
Patients 
With SLE 
50      13.12 1.81 0.35 0.72 
NS 
Control 50 13.24 1.58 
 
 This table shows no statistically significant difference between the 
transformed scores on Domain 4 of WHOQOL-BREF scale. This shows 
that the quality-of-life relating to environment is not affected in patients 
with SLE and is comparable to normal controls.  
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5.3.3.4  Relationship of Quality of life and psychiatric manifestations 
in SLE 
The quality of life is relatively unaffected amongst the patients 
with SLE except in the domain of psychological health. A correlation 
analysis was carried out between the scores on the psychological health 
domain of the WHOQOL-BREF Scale and the anxiety, depression 
elicited by various measures used in this study. The findings are shown 
below. 
Table 32 : Correlation Coefficients Of Anxiety, Depression 
                        And Quality Of Life 
Clinical data Rating scales Correlation coefficient ‘p’ value 
 
Domain 2 scores 
(1-100) 
 
HADS A 0.29 0.000055   Sig 
HADS D 0.31 0.000030  Sig 
HAM A 0.20 0.000992  Sig 
HAM D 0.11 0.016241  Sig 
 
Domain 2 scores 
(4-20) 
 
HADS A 0.12 0.013229  Sig 
HADS D 0.11 0.018430  Sig 
HAM A 0.20 0.001023  Sig 
HAM D 0.11 0.016749   Sig 
 
The table demonstrates the significant correlation between 
psychological domain scores in WHO quality of life scale and the 
psychiatric manifestations such as depression and anxiety as elicited by 
HADS,HAM-A, HAM-D. The results are in agreement with data reported 
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from the study by Doria et al in 2004 in Italy. According to Doria and 
colleagues impairment of quality-of-life does not depend directly on 
disease severity or permanent damage but these could lead to the 
emergence of anxiety and/or depressive symptoms in patients with SLE. 
Anxiety, depression and joint pain may actually impair the person’s 
quality-of-life.  
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6. LIMITATIONS 
 
This study had the objective to assess psychiatric manifestations 
such as anxiety, depression, psychotic symptoms and cognitive 
functioning among patients with systemic lupus erythematosus. The 
design employed was case control and used age, gender matched normal 
healthy volunteers from the relatives as controls. Comparison with 
normal controls helped to know that the psychiatric manifestations were 
more frequent in patients with SLE compared with normals. Yet to 
understand that psychiatric manifestations are more frequent in SLE 
compared with other chronic diseases, it would have been beneficial to 
use in addition a control group of another chronic condition such as 
rheumatoid arthritis. The psychiatric manifestations can be attributed to 
many factors including disease activity. It would have been useful if 
detailed clinical and laboratory data related to SLE was gathered; data on 
disease activity, definition of organ involvement, nuclear and 
antiphospholipid antibody detection, would have been useful to 
understand the relationship of psychiatric manifestations with these 
variables. In this study data was collected on basic clinical data such as 
duration of illness, type of treatment and dose of corticosteroids and 
hence there is limitation in the analysis of the relationship of determinants 
of psychiatric manifestations. Similarly it is learnt from the literature that 
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cognitive impairment in SLE is often due to direct central nervous system 
involvement and it can progress with the disease. Only longitudinal data 
can provide insights into the cognitive functioning and its progression 
with the disease and modification by treatment.  Being retrospective in 
design, the recall of all events that have occurred in the past can be 
difficult and recall bias is not uncommon in this type of design.  Finally, 
it should be stated that since the patients with SLE were only recruited 
from a tertiary teaching medical college hospital outpatient department, 
the results of the study cannot be generalised to all patients with SLE in 
the community settings. Despite these limitations, this study has 
highlighted the clinical importance of assessing the psychiatric 
manifestations such as anxiety, depression and cognitive functioning and 
quality of life in patients with SLE.    
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7. SUMMARY AND CONCLUSIONS 
 
Systemic lupus erythematosus, a multisystem disease has a variable 
course characterised by exacerbations and remissions; during the course 
of the illness, psychiatric manifestations are not uncommon. In view of 
the scarce Indian literature related to the study of psychiatric 
manifestations among patients with SLE, the present study has the 
objective of assessing the psychiatric manifestations, in particular, 
anxiety, depression, psychotic symptoms, cognitive functioning and 
quality of life among patients with SLE.  
A case control design was employed for the study, in which fifty 
consecutive patients with systemic lupus erythematosus attending the 
Rheumatology outpatient department at the Government General hospital, 
Chennai constituted the cases. The control group consisted of fifty 
healthy volunteers from the family members and relatives of the cases 
belonging to the same economic group. Care was taken to select controls 
matched for gender and age. 
Both patients and controls were administered a semi structured 
interview schedule that collected demographic, personal data; in addition 
relevant clinical data was gathered from the patients with SLE. They were 
interviewed using MINI PLUS to evaluate for psychiatric morbidity. The 
cases and controls were administered the following measures: Hamilton 
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Anxiety Rating Scale (HAM-A); Hamilton Depression Rating Scale 
(HAM-D); Hospital anxiety and depression scale (HADS); Brief 
psychiatric rating scale (BPRS); the Mini-Mental State Examination 
(MMSE); the Clock Drawing Test (CDT); and the World health 
organization quality of life (WHO QOL) BRFF. Further, the cases were 
assessed using SLE disease activity index (SLEDAI). The subjects in 
both the case and control groups provided written consent for 
participation in the study. The study design and protocol was approved by 
the Institutional Ethical Committee, Madras Medical College vide letter 
no 04082012. The data was analyzed using the computer software 
package Epi 6 Info. Significance level was set at p < 0.05.    
Among the patients with SLE, most were females (96%), from 
urban areas (86%), living in nuclear families (76%), married (56%) and 
educated up to higher secondary level (46%). The mean duration of SLE 
was about 2 years and the mean current dose of corticosteroids was 11.5 
mg (median dose 6.25 mg). 
Psychiatric manifestations such as anxiety and depression were 
frequently reported by patients with SLE. Among them, 26% patients had 
mild anxiety, 4% moderate level of anxiety and 2% had severe anxiety as 
rated by Hamilton anxiety scale (HAM-A). As rated by Hamilton 
depression rating scale (HAM-D) 22% had mild depression, 16% 
moderate depression and 14% severe depression.   Sixteen patients (32%) 
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had abnormal scores on anxiety scale in Hospital Anxiety and Depression 
Scale (HADS-A) and 24 patients (48%) had abnormal scores on 
depression scale (HADS-D).  Subdividing based on HAM-A & HAM-D 
scores, just more than a fifth of the patients with SLE (22%) reported 
mixed and depression symptoms to a mild or significant level. In this 
study most patients with SLE did not report significant level of psychotic 
symptoms. Using Clock drawing test, nine patients (18%) patients had a 
cut-off score of 3 or more signifying cognitive impairment. The cognitive 
impairment observed in these patients was independent of anxiety and 
depression.  None of the psychiatric manifestations such as anxiety, 
depression and cognitive impairment were associated with clinical 
variables such as duration of illness and dose of corticosteroids.   
The patients with SLE were compared with the control group for 
demographic variables and it was revealed that these two groups did not 
have statistically significant difference for the following variables: age, 
gender, marital status, education, income, occupation, family type and 
residence. Thus the cases and controls were matched for various 
demographic characteristics. Comparison was made between the two 
groups for psychiatric manifestations such as anxiety and depression. 
Anxiety as elicited by HAM-A was elevated in patients with SLE 
compared with normal controls (8.8 ± 6.1 vs. 4.9± 3.5) and this difference 
in the means was statistically significant (p 0.0002). Similarly the 
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difference in the means of anxiety scores in HAM-A between the cases 
and controls was statistically significant (5.9 ± 4 vs. 3.2± 2; p 0.01). 
Depression as shown by HAM-D was more in patients with SLE 
compared with normal controls (9.7 ± 7.2 vs. 5.1± 3.1) and this difference 
in the means was statistically significant (p 0.0001). Similarly the 
difference in the means of depression scores in HAM-D between the 
cases and controls was statistically significant (7.2 ± 4.9 vs. 4.1± 2.2; p 
0.01). Higher rates of anxiety and depression have been reported among 
patients with SLE in several studies (Hawro et al, 2011; Bachen et al, 
2009; Purandare et al, 1999; Mariana et al, 2010). Cognitive impairment 
was more among patients with SLE compared with control group and this 
is evidenced by greater mean scores in CDT for patients with SLE (1.96 ± 
0.9 vs. 1.12± 0.3; p 0.001). Similarly the difference between the mean 
scores of MMSE was statistically significant between the two groups  
(p 0.02).  
The two groups, patients with SLE and the normal controls were 
compared for the scores on the four domains – physical health, 
psychological health, social relationships and environment – in the 
WHOQOL - BREF scale. It was observed that there was no statistically 
significant difference between the two groups in three domains namely 
physical health, social relationships and environment whereas the 
difference between the two groups in psychological health was 
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statistically significant (47.7 ± 10.2 vs. 53.7± 9.2; p 0.03). There was 
significant correlation between psychological domain scores in WHO 
quality of life scale and the psychiatric manifestations such as depression 
and anxiety as elicited by HADS, HAM-A, HAM-D. 
 The study findings indicate that psychiatric manifestations such as 
anxiety and depression is common among patients with SLW; this is 
consistent with several studies on psychiatric morbidity among SLE 
reported from north America, Europe and Africa (Hawro et al, 2011; 
Kozora et al, 2006; Shehata et al, 2011). In this study clinical data such as 
duration of disease and dose of corticosteroids do not have a significant 
association with anxiety and depression. The elevated level of anxiety 
and depression can be due to multiple factors;  disease activity, direct 
involvement of the central nervous system and psychological reaction, 
stress of living with a chronic disease have all been proposed as possible 
reasons for the increased prevalence of anxiety/depression in patients 
with SLE. Whatever is the cause, the presence of psychiatric 
manifestations such as depression and anxiety can influence and cause 
impairment to quality of life among patients with SLE. In this study it is 
shown that the quality of life in the psychological domain is significantly 
impaired among patients with SLE compared with normal controls. The 
strong correlation between the psychiatric manifestations and the 
impairment to psychological domain of quality of life demonstrates the 
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significance of anxiety and depression amongst patients with SLE. Given 
the frequency as well the importance of its contribution to impairment to 
quality of life, it is suggested that all patients with SLE should be 
clinically screened for the presence of anxiety and depression. The study 
findings reveal that anxiety and depression can co-occur together in some 
of these patients and this should be taken into consideration while 
assessing patients for psychiatric morbidity.    
Cognitive impairment is observed more among patients with SLE 
compared with normal control; this observation is consistent with earlier 
studies on this topic (Maneeton et al, 2010).  In this present study it is 
shown that the cognitive impairment is independent of psychiatric 
manifestations such as anxiety and depression. Earlier studies have 
observed association between cognitive impairment and disease activity 
at the onset of the disease. Subclinical involvement is suggested as a 
reason for the cognitive impairment in patients with SLE. Longitudinal 
data on cognitive functioning in patients with SLE will help to understand 
the relationship between cognitive functioning and the disease activity.  
It is reported that in patients with SLE disturbance to quality of life 
does not appear to depend directly on the severity of SLE or permanent 
damage. On the other hand, the impairment may be attributable to the 
depressive and anxiety symptoms that may emerge in these patients 
(Doria et al, 2004). Thus, physicians treating SLE should be cognizant of 
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the increased prevalence of anxiety/depression among patients with SLE 
and understand the importance of early identification and treatment of 
anxiety / depressive symptoms. The physicians treating SLE may be 
given training to identify anxiety / depression in clinical settings and to 
provide treatment wherever necessary for patients with significant 
anxiety/depression. In general hospital settings, consultation-liaison 
between rheumatology and psychiatry departments will be helpful in 
delivering appropriate services that would mitigate the psychological 
distress among patients with SLE.  
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APPENDIX I - PROFORMA 
 
A – SOCIODEMOGRAPHIC DATA                                                     RCC NO:  
• Name : 
• Age : 
• Sex :  
• Education : Nil/School/SSLC/HSC/Graduate/PG/Professional 
• Occupation : Unemp/Emp/Non-Prof/Prof 
• Income : 
• Marital Status : Unmarried/Married/Separated/Divorced/Widow 
• Address : Urban/Rural 
• Religion : Hindu / Muslim/Christian/Others 
• Family Type : Nuclear/Joint 
• Number of children : Living alone/with children. 
 
B – ILLNESS DETAILS 
• Diagnosis  
• Duration of illness 
  Duration of treatment 
• Mode of treatment – Immunosupressants/ Steroids. 
  Current dose of steroids 
  Highest dose of steroids 
• Complication of disease (if any) 
• Other details (if any)  
• Drug compliance (Good, poor) 
• Perception of illness: 
Extent of knowledge about illness. 
• Previous treatment– Y/N. 
• Psychological reaction: Fear/anger/grief/acceptance/denial 
 
C- PAST HISTORY 
• Mental illness – Y/N 
• Medical illness – Y/N 
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• Past H/o of treatment for present complaints – other Modalities (specify) 
• Suicidal attempt / gestures 
• Drug intake → OC/Native treatment / HRT / Others 
 
D- FAMILY HISTORY 
• Type of family – Nuclear /Joint 
• Family H/o of mental illness / Suicide / Alcohol abuse / Similar illness. 
 
 
E-PERSONAL HISTORY 
• Birth & Development history 
• Menarche – age Menopause: 
• Married Y/N 
• Children Y/N 
• Smoker Y/N 
• Alcoholic Y/N 
• Ganja Y/N 
• Other substance use / abuse/dependence 
• Sexual dysfunction – absent / present 
(Frequency reduced / abstinent) 
 
F- PREMORBID PERSONALITY 
 
G – MENTAL STATUS EXAM 
 
• Conscious : Y/N 
• Rapport : Good/Possible/Not Possible 
• Gaze Contact : Maintained / Possible/ Not possible 
• Dressing and grooming: Adequate/Average/Poor 
• Psychomotor activity : Increased/Normal/Decreased 
• Attention : Aroused/Not aroused 
• Concentration : Sustained/ Not sustained 
• Memory : Immediate Y/N / Recent Y/N / Remote Y/N 
• Orientation : Time Y/N / Place: Y/N / Person: Y/N 
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TALK 
• Quantum : Decreased /Normal/Increased 
• Tone : Decreased/Normal/Increased 
• Tempo : Decreased/Normal/Increased 
• Reaction time : decreased/Normal/Increased 
• Prosody : Maintained/Not maintained 
• Relevant : Y/N 
• Coherent : Y/N 
THOUGHT 
• Formal thought disorder Y/N (Please specify) 
• Delusions : Y/N (Please Specify) 
• Hallucination : Y/N (Please Specify) 
• Depressive ideas : Y/N 
• Suicidal ideation : Y/N 
 
MOOD 
 
INSIGHT   
Absent / Partial /Present 
  
PHYSICAL EXAMINATION 
  
NEUROLOGICAL EXAMINATION 
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APPENDIX II 
 
HAMILTON DEPRESSION RATING SCALE ( HAM-D ) 
 
SL.NO ITEMS 0 1 2 3 4 
1 Depressed Mood      
2 Feeling Of Guilt      
3 Suicide      
4 Insomnia[ Early]     
5 Insomnia [Middle]    
6 Insomnia [Late]    
7 Work And Activities     - 
8 Retardation      
9 Agitation     
10 Anxiety [Psychic]      
11 Anxiety [ Somatic]      
12 Somatic Symptoms-Gastrointestinal     
13 Somatic Symptoms- General    
14 Genital Symptoms    
15 Hypochondriasis     - 
16 Loss Of Weight     - 
17 Insight     
18 Diurnal Variation     
19 Depersonalisation And 
Derealisation 
    
20 Paranoid Symptoms     
21 Obsessional And Compulsive 
Symptoms 
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APPENDIX III 
HAMILTON ANXIETY SCALE (HAM-A) 
SL NO ITEMS 0 1 2 3 4 
1 Anxious Mood      
2 Tension      
3 Fears      
4 Insomnia      
5 Intellectual      
6 Depressed Mood      
7 Somatic Compliants : Muscular      
8 Somatic Compliants : Sensory      
9 Cardiovascular      
10 Respiratory      
11 Gastrointestinal      
12 Genitourinary      
13 Autonomic      
14 Behaviour At Interview      
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APPENDIX IV 
HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS) 
 ITEMS 3 2 1 0 
A I feel tense or wound up     
A Frightened feel of some awful 
happening 
    
A Worrying  thoughts     
A I can sit at ease & relax     
A Feeling of butterflies in stomach     
A Feel restless     
A Feelings of panic     
  
 ITEMS 0 1 2 3 
D Still enjoy things      
D  Can laugh      
D Feel cheerful     
D Slowed down     
D Lost interest in appearance     
D Look forward to enjoy things     
D Entertainment      
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APPENDIX V 
 
BRIEF PSYCHIATRIC RATING SCALE (BPRS) 
 
SL NO ITEMS 0 1 2 3 4 5 6 7 
1 Somatic concern         
2 Anxiety          
3 Emotional withdrawal         
4 Conceptual disorganisation         
5 Guilt feelings         
6 Tension          
7 Mannerisms & posturing          
8 Grandiosity          
9 Depressive mood         
10 Hostility          
11 Suspiciousness          
12 Hallucinatory behavior         
13 Motor retardation         
14 Uncooperativeness          
15 Unusual thought content         
16 Blunted affect         
17 Excitement          
18 Disorientation          
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APPENDIX VI 
 
MINI MENTAL STATE EXAMINATION 
 
SL NO ITEMS SCORE 
1 TIME Orientation 5 
2 Place orientation 5 
3 Registration of 3 words 3 
4 Attention & calculation 5 
5 Recall of 3 words 3 
6 Naming  2 
7 Repetition  1 
8 Comprehension  3 
9 Reading  1 
10 Writing  1 
11 Drawing  1 
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APPENDIX VII 
 
CLOCK DRAWING TEST 
 
Score  Error(s)  Examples  
1  "Perfect"  No errors in the task  
2  Minor visuospatial errors  a) Mildly impaired spacing of times  
b) Draws times outside circle  
c) Turns page while writing so that some 
numbers appear  
upside down  
d) Draws in lines (spokes) to orient spacing  
3  Inaccurate representation 
of 10 after 11 when 
visuospatial organization 
is perfect or shows only 
minor deviations  
a) Minute hand points to 10  
b) Writes "10 after 11"  
c) Unable to make any denotation of time  
4  Moderate visuospatial 
disorganization of times 
such that accurate 
denotation of 10 after 11 is 
impossible  
a) Moderately poor spacing  
b) Omits numbers  
c) Perseveration: repeats circle or continues  
on past 12 to 13, 14, 15, etc.  
d) Right-left reversal: numbers drawn counter 
clockwise  
e) Dysgraphia: unable to write numbers 
accurately  
5  Severe level of 
disorganization as 
described in scoring of 4  
See examples for scoring of 4  
6  No reasonable 
representation of a clock  
a) No attempt at all  
b) No semblance of a clock at all  
c) Writes a word or name  
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BWônf£ RLYp Rôs 
BnYô[o   : 
TeúLtTô[o ùTVo  : 
RûXl×  : U]£ûRÜ úSô«u U]úNôo®u A±Ï±Ls  
                         ùRuTÓRÛm ARu RuûUÙm. 
BWônf£«u úSôdLm : 
RôeLs CkR UÚjÕY Bn®p LXkÕ ùLôsÞUôß AûZd¡ú\ôm. CkR 
BnYô]Õ GkRùYôÚ UÚjÕY RûXÂÓm CpXôRÕ. 
C§p EeLÞdÏ GkRùYôÚ BRôVúUô ApXÕ BTjúRô CÚdLôÕ. 
GeLs ûUVj§p SûPùT\ CÚdÏm Ko BWônf£dÏ EeLs JjÕûZl×m, 
Jl×RûXÙm úYiÓ¡ú\ôm. 
Ø¥ÜLû[ ApXÕ LÚjRLû[ ùY°«Óm úTôúRô ApXÕ 
BWônf£«uúTôúRô ReL[Õ ùTVûWúVô ApXÕ AûPVô[eLû[úVô 
ùY°«P UôhúPôm GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
CkR BWônf£«p TeúLtTÕ ReLÞûPV ®ÚlTj§u úT¬p Rôu 
CÚd¡\Õ. úUÛm ¿eLs GkúSWØm CkR BWônf£«­ÚkÕ ©uYôeLXôm 
GuTûRÙm ùR¬®jÕdùLôs¡ú\ôm. 
CkR £\l×l T¬úNôRû]L°u Ø¥ÜLû[ Bn®u Ø¥®uúTôÕ 
ReLÞdÏ A±®lúTôm GuTûRÙm ùR¬®jÕd ùLôs¡ú\ôm. 
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